Identifying immune responses in women treated with imiquimod for cervical lesions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to characterize the immune response and microbiological profile in women diagnosed with high-grade cervical intraepithelial lesions (CIN 3) treated with imiquimod. Participants will be divided into three groups: those receiving imiquimod treatment, those undergoing standard excisional treatment, and those with negative cytology and HPV. Blood and cervicovaginal samples will be collected at various points to analyze the immune response to treatment. The study seeks to improve understanding of how imiquimod works and its effects on patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients between 25 and 45 years of age (reproductive age);
* High-risk HPV carriers;
* Residents less than 300 km from the city of Barretos-São Paulo;
* With a histological diagnosis of high-grade cervical squamous intraepithelial lesion (CIN 3), obtained through colposcopy-guided biopsy performed at the Barretos Cancer Hospital (HCB);
* Acceptance of the Informed Consent Form.

Exclusion Criteria:

* Suspicion of invasive squamous cell carcinoma or Adenocarcinoma (in situ or invasive) by colposcopy and/or cytology;
* Pregnant or breastfeeding;
* Immunodeficiency condition;
* Previous treatment for high-grade cervical squamous intraepithelial lesion;
* Who have been immunized for HPV;
* Have used antibiotics in the last 30 days

Where it's running

• Barretos Cancer Hospital
  Barretos, Brazil Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cranberry products and the female vaginal and gut microbiome

  This trial will test whether taking a cranberry-based product changes the vaginal and gut microbiomes and related symptoms in generally healthy premenopausal women.

  Recruiting Ocean Spray Cranberries, Inc. · Chicago, Illinois · NCT07109713

• Anal cancer screening for men on PrEP

  This study will test how well anal swabs and DNA methylation testing find high-grade anal lesions (HSIL) and how common those lesions are in men who have sex with men using PrEP, and whether HSIL affects quality of life.

  Recruiting at 6 sites Universitair Ziekenhuis Brussel · Bruges and 7 other locations · NCT07029152

• Exploring the Vaginal Microbiome and Its Heredity

  This study is trying to see how the vaginal microbiome is passed down and shared among women and their partners by collecting samples and information from them.

  Recruiting University Hospital, Antwerp · Antwerp · NCT06912126

• Impact of vaginal bacteria on pregnancy success after embryo transfer

  This study is trying to see if the types of bacteria in the vagina affect the chances of getting pregnant after an embryo transfer for women undergoing fertility treatments.

  Recruiting at 10 sites Fundación IVI · Barcelona and 9 other locations · NCT06643065

• Using synbiotics to reduce the risk of preterm birth

  This study is testing if taking synbiotics can help women at high risk for preterm birth have healthier pregnancies by improving their vaginal microbiome.

  Recruiting at 9 sites Ziekenhuis Oost-Limburg · Edegem, Antwerpen and 8 other locations · NCT05966649

• Exploring the Uterine Microbiome in Women with Recurrent Pregnancy Loss

  This study looks at the bacteria in the uterus and vagina of women who have had multiple pregnancy losses to see how it compares to those who have had healthy pregnancies.

  Recruiting at 2 sites Mỹ Đức Hospital · Ho Chi Minh City, Ho Chi Minh City and 1 other locations · NCT05510622

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.